Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAISSANCE 2: SPN-817 in Adults With Focal Onset Seizures
NCT06798896Phase 2Recruiting
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Dec 2024
- Primary completion
- Aug 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in focal onset seizure comparing SPN-817 with Placebo (2 arms). Primary endpoint: Percent change from baseline in focal onset seizure frequency per 28 days over the Maintenance Period at 14 weeks. Started Dec 2024; status: recruiting.
02
Drugs
Huperzine A
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT06798896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798896.